Is Danaher Stock a Buy?
Investors in life sciences and diagnostics company Danaher (NYSE: DHR) have enjoyed a relatively good 2020 so far, with the stock rising 4.4% compared to a 11% decline in the S&P 500 index. In addition, it's the top-performing stock within its peer group. That said, the company's first-quarter sales came in lower than initial guidance, and CEO Tom Joyce believes its second-quarter core revenue growth will come "flat to down 10%."
In this context, is Danaher a stock to buy?
Source Fool.com